This multicenter open-label extension study conducted in France is designed to provide ATH434 orally BID to eligible patients who completed the Phase 2 study ATH434-201, and who may benefit from this treatment according to the evaluation by the Investigator.
Inclusion Criteria:
Exclusion Criteria:
clinicaltrials@alteritytx.com+1 888-556-7582
Participants who completed the prior ATH434-201 Phase 2 trial will receive ATH434 75 mg orally twice daily (BID). Treatment consists of an initial 12-month treatment phase, followed by an ongoing extension phase based on investigator assessment of continued clinical benefit, safety, and tolerability
Post-Trial Access to ATH434 for Patients With Multiple System Atrophy
Study of ATH434 in Participants with Multiple System Atrophy
A Biomarker Study of ATH434 in Participants With MSA
Open Label Study of ATH-1017 for Treatment of Mild to Moderate Alzheimer's Disease
Open Label Extension Study of AMX0035 in Patients With ALS
ACT-293987 in Pulmonary Arterial Hypertension
Safety, Tolerability, and Pharmacokinetics Study of ATH-1020
Open Label Extension Study to Evaluate the Safety and Tolerability of Oral Fampridine-Sustained Release (SR) in Canadian Participants With Multiple Sclerosis Who Participated in Acorda Extension Trials.